| + |
SB 203580 | down-regulates 
chemical inhibition
|
MAPK14 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-126055 |
|
|
Homo sapiens |
HeLa Cell |
| pmid |
sentence |
| 15208625 |
Pretreatment of hela cells with sb 203580, a pyridinyl imidazole compound that specifically inhibits p38 mitogen-activated protein kinase (mapk). It has previously been established that sb 203580 acts primarily to block the catalytic activity of p38 mapk. However, it has been suggested that in cells, the compounds could also inhibit p38 mapk activation by virtue of their ability to bind to the inactive enzyme. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-111064 |
|
|
Homo sapiens |
HeLa Cell |
| pmid |
sentence |
| 11606413 |
Pretreatment of hela cells with sb 203580, a pyridinyl imidazole compound that specifically inhibits p38 mitogen-activated protein kinase (mapk). It has previously been established that sb 203580 acts primarily to block the catalytic activity of p38 mapk. However, it has been suggested that in cells, the compounds could also inhibit p38 mapk activation by virtue of their ability to bind to the inactive enzyme. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-71024 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 10512765 |
Pretreatment of hela cells with sb 203580, a pyridinyl imidazole compound that specifically inhibits p38 mitogen-activated protein kinase (mapk). It has previously been established that sb 203580 acts primarily to block the catalytic activity of p38 mapk. However, it has been suggested that in cells, the compounds could also inhibit p38 mapk activation by virtue of their ability to bind to the inactive enzyme. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-75389 |
|
|
Homo sapiens |
HeLa Cell |
| pmid |
sentence |
| 10702313 |
Pretreatment of hela cells with sb 203580, a pyridinyl imidazole compound that specifically inhibits p38 mitogen-activated protein kinase (mapk). It has previously been established that sb 203580 acts primarily to block the catalytic activity of p38 mapk. However, it has been suggested that in cells, the compounds could also inhibit p38 mapk activation by virtue of their ability to bind to the inactive enzyme. |
|
| Publications: |
4 |
Organism: |
Homo Sapiens |
| Pathways: | FLT3-ITD signaling |
| + |
SB 203580 | down-regulates
chemical inhibition
|
MAPK11 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-126052 |
|
|
Homo sapiens |
Myoblast |
| pmid |
sentence |
| 15208625 |
Pharmacological blockade of p38?/? Kinases by sb203580 inhibits the myogenic program3_5 by repressing the transcription of early (myogenin;myog) and late (muscle-creatine kinase;ckm) muscle genes in myoblasts induced to differentiate |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
SB 203580 | down-regulates activity
chemical inhibition
|
MAPK14 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-258279 |
|
|
in vitro |
|
| pmid |
sentence |
| 22037378 |
Our data set represents the most detailed comprehensive assessment of the reactivity of known and clinical kinase inhibitors across the kinome published to date. | The data also show that for at least 15 of the 27 kinases that are the primary, intended targets for the compounds tested and that are represented in the assay panel, selective inhibitors, as assessed by both absolute selectivity across the kinome and selectivity relative to the primary target, are among the 72 tested here. |
|
| Publications: |
1 |
Organism: |
In Vitro |
| Pathways: | FLT3-ITD signaling |
3.0
SB 203580
